{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:57:12Z","timestamp":1790600232924,"version":"4.1.0"},"reference-count":37,"publisher":"Walter de Gruyter GmbH","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jcim-2026-0258_abs_002\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      This study evaluated the hepatoprotective effect of an ethanolic extract of\u00a0\n                      <jats:italic>A. catechu<\/jats:italic>\n                      \u00a0stem bark (ACSB) in metabolic dysfunction-associated steatotic liver disease (MASLD) induced by a high-fat and high-fructose (HFHFr) diet.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2026-0258_abs_003\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The HFHFr model was developed over 10\u00a0weeks. After six\u00a0weeks of induction, ACSB was administered orally at 100 and 200\u202fmg\/kg for four weeks, while the standard group received pioglitazone (3\u202fmg\/kg). Biochemical, lipid, inflammatory, and histopathological parameters were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2026-0258_abs_004\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HFHFr administration produced significant alterations in lipid, biochemical, inflammatory, and liver function parameters, along with histopathological changes. ACSB treatment improved these alterations in a dose-dependent manner, with 200\u202fmg\/kg showing effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2026-0258_abs_005\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ACSB demonstrated hepatoprotective and antihyperlipidemic effects against HFHFr-induced MASLD, potentially associated with its flavonoid and polyphenolic constituents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jcim-2026-0258","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:57:47Z","timestamp":1790596667000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of hepatoprotective effect of\n                    <i>Acacia catechu<\/i>\n                    stem bark extract on high fat and high fructose diet induced metabolic dysfunction-associated steatotic liver disease in experimental animals"],"prefix":"10.1515","author":[{"given":"Dinesh","family":"Chandrakant Vhanale","sequence":"first","affiliation":[{"name":"Department of Pharmacology , Progressive Education Society\u2019s Modern College of Pharmacy , Pune , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti Dinesh","family":"Bandawane","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , Progressive Education Society\u2019s Modern College of Pharmacy , Pune , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratiksha Kantilal","family":"Hajare","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , Progressive Education Society\u2019s Modern College of Pharmacy , Pune , India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"2026092811574416108_j_jcim-2026-0258_ref_001","doi-asserted-by":"crossref","unstructured":"Paik, JM, Henry, L, Younossi, Y, Ong, J, Alqahtani, S, Younossi, ZM. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. [Internet]. Hepatol Commun 2023;7. Available from: https:\/\/doi.org\/10.1097\/hc9.0000000000000251.","DOI":"10.1097\/HC9.0000000000000251"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_002","doi-asserted-by":"crossref","unstructured":"Riazi, K, Azhari, H, Charette, JH, Underwood, FE, King, JA, Afshar, EE, et al.. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. [Internet]. Lancet Gastroenterol Hepatol 2022;7:851\u201361. https:\/\/doi.org\/10.1016\/s2468-1253(22)00165-0.","DOI":"10.1016\/S2468-1253(22)00165-0"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_003","doi-asserted-by":"crossref","unstructured":"Rinella, ME, Lazarus, JV, Ratziu, V, Francque, SM, Sanyal, AJ, Kanwal, F, et al.. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. [Internet]. Hepatology 2023;78:1966\u201386. https:\/\/doi.org\/10.1097\/hep.0000000000000520.","DOI":"10.1097\/HEP.0000000000000520"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_004","doi-asserted-by":"crossref","unstructured":"Brunt, EM, Kleiner, DE, Carpenter, DH, Rinella, M, Harrison, SA, Loomba, R, et al.. NAFLD: reporting histologic findings in clinical practice. [Internet]. Hepatology 2020;73:2028\u201338. https:\/\/doi.org\/10.1002\/hep.31599.","DOI":"10.1002\/hep.31599"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_005","doi-asserted-by":"crossref","unstructured":"Castera, L, Friedrich-Rust, M, Loomba, R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. [Internet]. Gastroenterology 2019;156:1264\u201381.e4. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.036.","DOI":"10.1053\/j.gastro.2018.12.036"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_006","doi-asserted-by":"crossref","unstructured":"Younossi, ZM, Stepanova, M, Ong, J, Trimble, G, AlQahtani, S, Younossi, I, et al.. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United\u00a0States. [Internet]. Clin Gastroenterol Hepatol 2020;19:580\u20139. https:\/\/doi.org\/10.1016\/j.cgh.2020.05.064.","DOI":"10.1016\/j.cgh.2020.05.064"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_007","doi-asserted-by":"crossref","unstructured":"Jegatheesan, P, De Bandt, J. Fructose and NAFLD: the multifaceted aspects of fructose metabolism. [Internet]. Nutrients 2017;9:230. https:\/\/doi.org\/10.3390\/nu9030230.","DOI":"10.3390\/nu9030230"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_008","doi-asserted-by":"crossref","unstructured":"Softic, S, Cohen, DE, Kahn, CR. Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. [Internet]. Dig Dis Sci 2016;61:1282\u201393. https:\/\/doi.org\/10.1007\/s10620-016-4054-0.","DOI":"10.1007\/s10620-016-4054-0"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_009","doi-asserted-by":"crossref","unstructured":"Lanaspa, MA, Sanchez-Lozada, LG, Choi, YJ, Cicerchi, C, Kanbay, M, Roncal-Jimenez, CA, et al.. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress. [Internet]. J\u00a0Biol Chem 2012;287:40732\u201344. https:\/\/doi.org\/10.1074\/jbc.m112.399899.","DOI":"10.1074\/jbc.M112.399899"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_010","doi-asserted-by":"crossref","unstructured":"Hannou, SA, Haslam, DE, McKeown, NM, Herman, MA. Fructose metabolism and metabolic disease. [Internet]. J\u00a0Clin Investig 2018;128:545\u201355. https:\/\/doi.org\/10.1172\/jci96702.","DOI":"10.1172\/JCI96702"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_011","doi-asserted-by":"crossref","unstructured":"Taskinen, MR, Packard, CJ, Bor\u00e9n, J. Dietary fructose and the metabolic syndrome. [Internet]. Nutrients 2019;11:1987. https:\/\/doi.org\/10.3390\/nu11091987.","DOI":"10.3390\/nu11091987"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_012","doi-asserted-by":"crossref","unstructured":"Sun, SZ, Empie, MW. Fructose metabolism in humans\u00a0\u2013\u00a0what isotopic tracer studies tell us. [Internet]. Nutr Metabol 2012;9:89. https:\/\/doi.org\/10.1186\/1743-7075-9-89.","DOI":"10.1186\/1743-7075-9-89"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_013","doi-asserted-by":"crossref","unstructured":"Friedman, SL, Neuschwander-Tetri, BA, Rinella, M, Sanyal, AJ. Mechanisms of NAFLD development and therapeutic strategies. [Internet]. Nat Med 2018;24:908\u201322. https:\/\/doi.org\/10.1038\/s41591-018-0104-9.","DOI":"10.1038\/s41591-018-0104-9"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_014","doi-asserted-by":"crossref","unstructured":"Younossi, ZM, Corey, KE, Lim, JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. [Internet]. Gastroenterology 2020;160:912\u20138. https:\/\/doi.org\/10.1053\/j.gastro.2020.11.051.","DOI":"10.1053\/j.gastro.2020.11.051"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_015","doi-asserted-by":"crossref","unstructured":"Xu, Y, Guo, W, Zhang, C, Chen, F, Tan, HY, Li, S, et al.. Herbal medicine in the treatment of non-alcoholic fatty liver diseases-efficacy, action mechanism, and clinical application. [Internet]. Front Pharmacol 2020;11:601. https:\/\/doi.org\/10.3389\/fphar.2020.00601.","DOI":"10.3389\/fphar.2020.00601"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_016","doi-asserted-by":"crossref","unstructured":"Wang, YY, Chiang, HS, Cheng, CY, Wu, YN, Lin, YC, Lin, YC, et al.. SLC9A3 protein is critical for acrosomal formation in postmeiotic male germ cells. [Internet]. Int J Mol Sci 2017;19:103. https:\/\/doi.org\/10.3390\/ijms19010103.","DOI":"10.3390\/ijms19010103"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_017","doi-asserted-by":"crossref","unstructured":"Yao, H, Qiao, YJ, Zhao, YL, Tao, XF, Xu, LN, Yin, LH, et al.. Herbal medicines and nonalcoholic fatty liver disease. [Internet]. World J Gastroenterol 2016;22:6890. https:\/\/doi.org\/10.3748\/wjg.v22.i30.6890.","DOI":"10.3748\/wjg.v22.i30.6890"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_018","doi-asserted-by":"crossref","unstructured":"Jadeja, R, Devkar, RV, Nammi, S. Herbal medicines for the treatment of nonalcoholic steatohepatitis: current scenario and future prospects. [Internet]. Evid Based Complement Alternat Med 2014;2014:648308. https:\/\/doi.org\/10.1155\/2014\/648308.","DOI":"10.1155\/2014\/648308"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_019","doi-asserted-by":"crossref","unstructured":"Yang, XF, Lu, M, You, L, Gen, H, Yuan, L, Tian, T, et al.. Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology. [Internet]. Chin Med 2021;16:62. https:\/\/doi.org\/10.1186\/s13020-021-00470-x.","DOI":"10.1186\/s13020-021-00470-x"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_020","doi-asserted-by":"crossref","unstructured":"Yan, T, Yan, N, Wang, P, Xia, Y, Hao, H, Wang, G, et al.. Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. [Internet]. Acta Pharm Sin B 2019;10:3\u201318. https:\/\/doi.org\/10.1016\/j.apsb.2019.11.017.","DOI":"10.1016\/j.apsb.2019.11.017"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_021","doi-asserted-by":"crossref","unstructured":"Hiraganahalli, BD, Chinampudur, VC, Dethe, S, Mundkinajeddu, D, Pandre, MK, Balachandran, J, et al.. Hepatoprotective and antioxidant activity of standardized herbal extracts. Pharmacogn Mag 2012;8:116\u201323.","DOI":"10.4103\/0973-1296.96553"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_022","doi-asserted-by":"crossref","unstructured":"Stohs, SJ, Bagchi, D. Antioxidant, anti\u2010inflammatory, and chemoprotective properties of Acacia catechu heartwood extracts. [Internet]. Phytother Res 2015;29:818\u201324. https:\/\/doi.org\/10.1002\/ptr.5335.","DOI":"10.1002\/ptr.5335"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_023","doi-asserted-by":"crossref","unstructured":"Li, XC, Liu, C, Yang, LX, Chen, RY. Phenolic compounds from the aqueous extract of Acacia catechu. [Internet]. J\u00a0Asian Nat Prod Res 2011;13:826\u201330. https:\/\/doi.org\/10.1080\/10286020.2011.597384.","DOI":"10.1080\/10286020.2011.597384"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_024","doi-asserted-by":"crossref","unstructured":"Paul, A, Rajiung, M, Zaman, K, Chaudhary, SK, Bhat, HR, Shakya, A. An overview of phytochemical and pharmacological profile of Morus Alba linn. [Internet]. Curr Bioact Compd 2020;17. Available from: https:\/\/doi.org\/10.2174\/1573407216666201228114004.","DOI":"10.2174\/1573407216666201228114004"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_025","doi-asserted-by":"crossref","unstructured":"Camps, SG, Kaur, B, Lim, J, Loo, YT, Pang, E, Ng, T, et al.. Improved glycemic control and variability: application of healthy ingredients in Asian staples. [Internet]. Nutrients 2021;13:3102. https:\/\/doi.org\/10.3390\/nu13093102.","DOI":"10.3390\/nu13093102"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_026","doi-asserted-by":"crossref","unstructured":"Abunofal, O, Mohan, C. Salubrious effects of green tea catechins on fatty liver disease: a systematic review. [Internet]. Medicine 2022;9:20. https:\/\/doi.org\/10.3390\/medicines9030020.","DOI":"10.3390\/medicines9030020"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_027","doi-asserted-by":"crossref","unstructured":"Eslam, M, Newsome, PN, Sarin, SK, Anstee, QM, Targher, G, Romero-Gomez, M, et al.. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. [Internet]. J\u00a0Hepatol 2020;73:202\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039.","DOI":"10.1016\/j.jhep.2020.07.045"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_028","doi-asserted-by":"crossref","unstructured":"Hashmi, KA, Giglio, RV, Stoian, AP, Patti, AM, Waili, KA, Rasadi, KA, et al.. Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies. [Internet]. Front Nutr 2024;11:1355732. https:\/\/doi.org\/10.3389\/fnut.2024.1355732.","DOI":"10.3389\/fnut.2024.1355732"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_029","doi-asserted-by":"crossref","unstructured":"Yang, K, Song, M. New insights into the pathogenesis of metabolic-associated fatty liver disease (MAFLD): gut\u2013liver\u2013heart crosstalk. [Internet]. Nutrients 2023;15:3970. https:\/\/doi.org\/10.3390\/nu15183970.","DOI":"10.3390\/nu15183970"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_030","doi-asserted-by":"crossref","unstructured":"Tilg, H, Moschen, AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. [Internet]. Hepatology 2010;52:1836\u201346. https:\/\/doi.org\/10.1002\/hep.24001.","DOI":"10.1002\/hep.24001"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_031","doi-asserted-by":"crossref","unstructured":"Ipsen, DH, Lykkesfeldt, J, Tveden-Nyborg, P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. [Internet]. Cell Mol Life Sci 2018;75:3313\u201327. https:\/\/doi.org\/10.1007\/s00018-018-2860-6.","DOI":"10.1007\/s00018-018-2860-6"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_032","doi-asserted-by":"crossref","unstructured":"Ma, J, Zheng, Y, Tang, W, Yan, W, Nie, H, Fang, J, et al.. Dietary polyphenols in lipid metabolism: a role of gut microbiome. [Internet]. Animal Nutrition 2020;6:404\u20139. https:\/\/doi.org\/10.1016\/j.aninu.2020.08.002.","DOI":"10.1016\/j.aninu.2020.08.002"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_033","doi-asserted-by":"crossref","unstructured":"Babu, PVA, Liu, D, Gilbert, ER. Recent advances in understanding the anti-diabetic actions of dietary flavonoids. [Internet]. J\u00a0Nutr Biochem 2013;24:1777\u201389. https:\/\/doi.org\/10.1016\/j.jnutbio.2013.06.003.","DOI":"10.1016\/j.jnutbio.2013.06.003"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_034","doi-asserted-by":"crossref","unstructured":"Neuschwander-Tetri, BA. Non-alcoholic fatty liver disease. [Internet]. BMC Med 2017;15:45. https:\/\/doi.org\/10.1186\/s12916-017-0806-8.","DOI":"10.1186\/s12916-017-0806-8"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_035","doi-asserted-by":"crossref","unstructured":"Buzzetti, E, Pinzani, M, Tsochatzis, EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). [Internet]. Metabolism 2016;65:1038\u201348. https:\/\/doi.org\/10.1016\/j.metabol.2015.12.012.","DOI":"10.1016\/j.metabol.2015.12.012"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_036","doi-asserted-by":"crossref","unstructured":"Panche, AN, Diwan, AD, Chandra, SR. Flavonoids: an overview. [Internet]. J\u00a0Nutr Sci 2016;5:e47. https:\/\/doi.org\/10.1017\/jns.2016.41.","DOI":"10.1017\/jns.2016.41"},{"key":"2026092811574416108_j_jcim-2026-0258_ref_037","doi-asserted-by":"crossref","unstructured":"Yki-J\u00e4rvinen, H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. [Internet]. Lancet Diabetes Endocrinol 2014;2:901\u201310. https:\/\/doi.org\/10.1016\/s2213-8587(14)70032-4.","DOI":"10.1016\/S2213-8587(14)70032-4"}],"container-title":["Journal of Complementary and Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2026-0258\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2026-0258\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:57:57Z","timestamp":1790596677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2026-0258\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":37,"alternative-id":["10.1515\/jcim-2026-0258"],"URL":"https:\/\/doi.org\/10.1515\/jcim-2026-0258","relation":{},"ISSN":["2194-6329","1553-3840"],"issn-type":[{"value":"2194-6329","type":"print"},{"value":"1553-3840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]}}}